Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma

NCT00494091 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG: Temsirolimus (CCI-779)
DRUG: Temsirolimus (CCI-779)

Sponsor

Pfizer